Tags

Type your tag names separated by a space and hit enter

Cannabinoids for gastrointestinal diseases: potential therapeutic applications.
Expert Opin Investig Drugs. 2003 Jan; 12(1):39-49.EO

Abstract

Delta(9)-Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and synthetic cannabinoids, exert many biological functions by activating two types of cannabinoid receptors, CB(1) and CB(2) receptors. CB(1) receptors have been detected on enteric nerves, and pharmacological effects of their activation include gastroprotection, reduction of gastric and intestinal motility and reduction of intestinal secretion. The digestive tract also contains endogenous cannabinoids (i.e., the endocannabinoids anandamide and 2-aracidonylglycerol) and mechanisms for endocannabinoid inactivation (i.e., endocannabinoids uptake and enzymatic degradation). Cannabinoid receptors, endocannabinoids and the proteins involved in endocannabinoids inactivation are collectively referred as the 'endogenous cannabinoid system'. A pharmacological modulation of the endogenous cannabinoid system could provide new therapeutics for the treatment of a number of gastrointestinal diseases, including nausea and vomiting, gastric ulcers, irritable bowel syndrome, Crohn's disease, secretory diarrhoea, paralytic ileus and gastroesophageal reflux disease. Some cannabinoids are already in use clinically, for example, nabilone and delta(9)-tetrahydrocannabinol are used as antiemetics.

Authors+Show Affiliations

Department of Experimental Pharmacology, University of Naples Federico II, via D. Montesano 49, 80131 Naples, Italy.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

12517253

Citation

Di Carlo, Giulia, and Angelo A. Izzo. "Cannabinoids for Gastrointestinal Diseases: Potential Therapeutic Applications." Expert Opinion On Investigational Drugs, vol. 12, no. 1, 2003, pp. 39-49.
Di Carlo G, Izzo AA. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin Investig Drugs. 2003;12(1):39-49.
Di Carlo, G., & Izzo, A. A. (2003). Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opinion On Investigational Drugs, 12(1), 39-49.
Di Carlo G, Izzo AA. Cannabinoids for Gastrointestinal Diseases: Potential Therapeutic Applications. Expert Opin Investig Drugs. 2003;12(1):39-49. PubMed PMID: 12517253.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabinoids for gastrointestinal diseases: potential therapeutic applications. AU - Di Carlo,Giulia, AU - Izzo,Angelo A, PY - 2003/1/9/pubmed PY - 2003/3/27/medline PY - 2003/1/9/entrez SP - 39 EP - 49 JF - Expert opinion on investigational drugs JO - Expert Opin Investig Drugs VL - 12 IS - 1 N2 - Delta(9)-Tetrahydrocannabinol (the active ingredient of marijuana), as well as endogenous and synthetic cannabinoids, exert many biological functions by activating two types of cannabinoid receptors, CB(1) and CB(2) receptors. CB(1) receptors have been detected on enteric nerves, and pharmacological effects of their activation include gastroprotection, reduction of gastric and intestinal motility and reduction of intestinal secretion. The digestive tract also contains endogenous cannabinoids (i.e., the endocannabinoids anandamide and 2-aracidonylglycerol) and mechanisms for endocannabinoid inactivation (i.e., endocannabinoids uptake and enzymatic degradation). Cannabinoid receptors, endocannabinoids and the proteins involved in endocannabinoids inactivation are collectively referred as the 'endogenous cannabinoid system'. A pharmacological modulation of the endogenous cannabinoid system could provide new therapeutics for the treatment of a number of gastrointestinal diseases, including nausea and vomiting, gastric ulcers, irritable bowel syndrome, Crohn's disease, secretory diarrhoea, paralytic ileus and gastroesophageal reflux disease. Some cannabinoids are already in use clinically, for example, nabilone and delta(9)-tetrahydrocannabinol are used as antiemetics. SN - 1354-3784 UR - https://www.unboundmedicine.com/medline/citation/12517253/Cannabinoids_for_gastrointestinal_diseases:_potential_therapeutic_applications_ L2 - http://www.tandfonline.com/doi/full/10.1517/13543784.12.1.39 DB - PRIME DP - Unbound Medicine ER -